Zhejiang Hisun Pharmaceutical (SHA:600267) received the marketing approval of China's National Medical Products Administration for its eltrombopag raw drug ingredient, according to the company's filing on the Shanghai Stock Exchange.
The Chinese pharmaceutical company invested 11.9 million yuan into the raw drug ingredient, which is used for chronic immune (idiopathic) thrombocytopenia in patients who have not responded well to treatments, such as glucocorticoids and immunoglobulins, the Tuesday filing added.
Shares of the company rose more than 3% in recent trade.
Price (RMB): ¥7.90, Change: ¥+0.24, Percent Change: +3.13%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments